Information Provided By: 
Fly News Breaks for June 19, 2015
ALDR, LLY, AMGN, TEVA
Jun 19, 2015 | 07:23 EDT
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
News For TEVA;AMGN;LLY;ALDR From the Last 2 Days
There are no results for your query TEVA;AMGN;LLY;ALDR
